XTL Biopharmaceuticals Ltd. (XTLB)
- Previous Close
2.4000 - Open
2.4900 - Bid --
- Ask --
- Day's Range
2.4050 - 2.4900 - 52 Week Range
0.7500 - 4.9900 - Volume
5,252 - Avg. Volume
749,125 - Market Cap (intraday)
13.198M - Beta (5Y Monthly) 1.03
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
www.xtlbio.comRecent News: XTLB
Performance Overview: XTLB
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XTLB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XTLB
Valuation Measures
Market Cap
13.02M
Enterprise Value
10.82M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.28
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-6.31
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-13.06%
Return on Equity (ttm)
-62.00%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-2.25M
Diluted EPS (ttm)
-0.4000
Balance Sheet and Cash Flow
Total Cash (mrq)
2.21M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--